Eric Ortlund, PhD
![]() |
(he/him) |
Professor, Department of Biochemistry, School of Medicine
Director of Emory Integrated Metabolomics and Lipidomics Core Facility (EIMLC), Department of Biochemistry, School of Medicine
Graduate Programs
- Full Member - Biochemistry, Cell and Developmental Biology
- Full Member - Molecular and Systems Pharmacology
Education
PhD, University of South Carolina, 2002Contact Information
Email: eortlun@emory.edu
Phone: 404-727-5014
Address:
O. Wayne Rollins Research Center, Room 4017
1510 Clifton Road NE
Atlanta, GA 30322
1940-001-1AE
With the outbreak of SARS-CoV-2, we were well-placed to redirect our expertise to investigate detection and neutralizing antibodies using Cryo-EM, and to predict antibody escape using deep mutational scanning (DMS). Working closely with the RADx initiative, our methods have proven useful to multiple companies seeking FDA approval for their novel COVID-19 diagnostic methods. Currently we are expanding our technology to tackle other arising infectious diseases of concern and to design new therapeutic proteins.
Targeting the orphan nuclear receptor LRH-1 with small molecules
Funding Agency: NIH NIDDK
Project Dates: 07/01/2017 to 06/30/2028
Regulation of CSE-Derived Hydrogen Sulfide in the Heart
Funding Agency: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Project Dates: 04/01/2023 to 03/30/2027
R01 Lipid-Mediated Control of Acetyl-CoA Metabolism in the Pathogenesis of NAFLD
Funding Agency: NIH NIDDK
Project Dates: 01/01/2024 to 01/01/2029
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
Funding Agency: NIDDK
Project Dates: 07/01/2023 to 06/29/2027
Rapid identification of human antibodies recognizing influenza hemagglutinin epitopes undergoing antigenic drift
Funding Agency: Center for Disease Control (CDC)
Project Dates: 12/01/2023 to 11/30/2025
Targeting LRH-1 to treat ulcerative colitis
Funding Agency: Department of Defense
Project Dates: 05/15/2023 to 05/14/2027

André Cuevas
Biochemistry, Cell and Developmental Biology
Entrance Year: 2019
Topic: Development of small molecule modulators for steroidogenic factor-1 activity

Raining Huo
Biochemistry, Cell and Developmental Biology
Entrance Year: 2021

Molly Little (she/her)
Biochemistry, Cell and Developmental Biology
Entrance Year: 2021
Topic: Characterization of small molecule-mediated activity of Them1

Shakshi Patel
Molecular and Systems Pharmacology
Entrance Year: 2022
Topic: LRH-1 Antagonism as a Novel Approach for Treating Breast Cancer
Hannah Lute
Biochemistry, Cell and Developmental Biology
MS, 2023
Michael Cato
Biochemistry, Cell and Developmental Biology
PhD, 2023
"DEVELOPMENT AND CHARACTERIZATION OF SYNTHETIC MODULATORS OF NUCLEAR RECEPTOR LRH-1: DRIVING DIVERGENT SIGNALING USING A COMMON MOLECULAR SCAFFOLD"
Samuel Druzak
Molecular and Systems Pharmacology
PhD, 2022
"Differential regulation of peroxisome proliferator activating receptors (PPARs) via host and microbial derived processes"
Emma D'Agostino
Biochemistry, Cell and Developmental Biology
PhD, 2020
"Structure-Function Analysis of NR5A Nuclear Receptors"
Matthew Tillman
Molecular and Systems Pharmacology
PhD, 2020
"A STRUCTURAL AND BIOCHEMICAL INVESTIGATION OF HOW LIPID MESSENGERS ACT THROUGH LIPID TRANSFER PROTEINS TO REGULATE METABOLISM AND LONGEVITY"
R Esposito
Biochemistry, Cell and Developmental Biology
MS, 2018
Emily Weikum
Biochemistry, Cell and Developmental Biology
PhD, 2017
"Allosteric Modulation of Nuclear Receptor Function"
Will Hudson
Molecular and Systems Pharmacology
PhD, 2015
"Two for one: The glucocorticoid receptor as a DNA- and RNA-binding protein"
Eric Armstrong
Molecular and Systems Pharmacology
PhD, 2014
"The Role of Fatty Acid Binding Protein 5 (FABP5) in Peroxisome Proliferator-Activated Receptor β/δ (PPARβ/δ)-Mediated Fatty Acid and Retinoic Acid Signaling: A Structural Perspective"
Jennifer Colucci
Biochemistry, Cell and Developmental Biology
PhD, 2014
"Identifying networks that drive steroid receptor cross pharmacology"
Paul Musille
Molecular and Systems Pharmacology
PhD, 2014
"Structural mechanism for NR5a activation"